We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Accrol Group Holdings Plc | LSE:ACRL | London | Ordinary Share | GB00BZ6VT592 | ORD GBP0.001 |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 38.45 | 38.40 | 38.50 | 214,020 | 09:31:51 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Convrt Paper,paperbd Pds,nec | 241.91M | -5.7M | -0.0179 | -21.48 | 122.61M |
TIDMACRL
RNS Number : 5867E
Accrol Group Holdings PLC
14 March 2022
14 March 2022
This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) 596/2014 as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018 ("MAR"), and is disclosed in accordance with the Company's obligations under Article 17 of MAR.
Accrol Group Holdings plc
("Accrol", the "Company" or the "Group")
Update on Leicester Tissue Company Share Purchase Agreement
Accrol (AIM:ACRL), the UK's leading independent tissue convertor, is pleased to announce that, following final settlement with the vendor of Leicester Tissue Company ("LTC"), no sums are due to be paid nor equity issued under the deferred consideration arrangements relating to the acquisition of LTC.
Further details of the acquisition of LTC are contained in the announcement issued by the Company on 2 November 2020 titled "Acquisition and Launch of ABB".
Dan Wright, Chairman of Accrol, said: "LTC has proven an extremely valuable addition to the Accrol manufacturing footprint. Its operations are now fully integrated within the wider Accrol business, allowing us to accommodate considerable growth and realise significant efficiencies and synergies across the Group."
For further information, please contact: Accrol Group Holdings plc Dan Wright, Executive Chairman Via Belvedere Communications Gareth Jenkins, Chief Executive Officer Richard Newman, Chief Financial Officer Zeus Capital Limited (Nominated Adviser & Broker) Dan Bate / Jordan Warburton Tel: +44 (0) 161 831 1512 Dominic King Tel: +44 (0) 203 829 5000 Liberum Capital Limited (Joint Broker) Tel: +44 (0) 20 3100 2222 Clayton Bush / Edward Thomas Belvedere Communications Limited Cat Valentine Tel: +44 (0) 7715 769 078 Keeley Clarke Tel: +44 (0) 7967 816 525 accrolpr@belvederepr.com
Overview of Accrol
Accrol Group Holdings plc is a leading tissue converter and supplier of toilet tissues, kitchen rolls, facial tissues, and wet wipes to many of the UK's leading discounters and grocery retailers across the UK. Following the acquisitions of LTC in Leicester and JD in Flint, North Wales, the Group now operates from six manufacturing sites, including four in Lancashire, which generate revenues totalling c.16% of the GBP2.1bn UK retail tissue market.
For more information, please visit www.accrol.co.uk .
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
FURBCGDXXBBDGDX
(END) Dow Jones Newswires
March 14, 2022 03:00 ET (07:00 GMT)
1 Year Accrol Chart |
1 Month Accrol Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions